Friday, April 06, 2012

Clinical Trial Advice For Investors From Two Pros - Forbes


Nissen is known to investors as one of the cardiologists who first raised alarms about Merck‘s Vioxx, a pain pill that was later withdrawn from the market, then who first raised concerns about GlaxoSmithKline‘s diabetes drug Avandia, which had its use severely restricted. (He deals quickly with the Avandia story on page 213, of Heart411, in the section on what patients should know about meta-analysis, the technique for combining clinical trials that was used to impugn the drug.) The book represents a clear look into a set of viewpoints on clinical trial design useful to anyone who is interested in how companies develop medicines — or whether to take them.

Posted via email from Jack's posterous

No comments: